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Background. The effectiveness of trivalent inﬂuenza vaccination has been conﬁrmed in several studies. To date,
it is not known whether repeated exposure and vaccination to inﬂuenza promote production of cross-reactive anti-
bodies. Furthermore, how strains encountered earlier in life imprint the immune response is currently poorly
understood.
Methods. To determine the prevalence for human homo- and heterosubtypic antibody responses, we scruti-
nized serum samples from 305 healthy volunteers for hemagglutinin-binding and -neutralizing antibodies against
several strains and subtypes of inﬂuenza A. Statistical analyses were then performed to establish the association of
measured values with potential predictors.
Results. It was found that vaccination not only promoted higher binding and neutralizing antibody titers to
homosubtypic inﬂuenza isolates but also increased heterosubtypic human immune responses. Both binding and
neutralizing antibody titers in relation with age of the donors mirrored the course of the different inﬂuenza
strain circulation during the last century. Advanced age appeared to be of advantage for both binding and neu-
tralizing titers to most subtypes. In contrast, the ﬁrst virus subtype encountered was found to imprint to some
degree subsequent antibody responses. Antibodies to recent strains, however, primarily seemed to be promoted
by vaccination.
Conclusions. We provide evidence that vaccinations stimulate both homo- and heterosubtypic immune
responses in young and middle-aged as well as more senior individuals. Our analyses suggest that inﬂuenza vac-
cinations not only prevent infection against currently circulating strains but can also stimulate broader humoral
immune responses that potentially attenuate infections with zoonotic or antigenically shifted strains.
Keywords. inﬂuenza virus; heterosubtypic antibodies; prevalence; predictors.
The antibody response to inﬂuenza viruses is highly
strain- and subtype-speciﬁc, and is primarily directed
against the variable immunodominant apical epitopes
on the hemagglutinin (HA) protein [1]. Vaccine-
induced antibodies are therefore only effective against
viruses closely related to the inoculated strains, and
immunization needs to be revised annually to reﬂect
the antigenic outﬁt of the viruses predicted to be predomi-
nant in the following inﬂuenza season. The breadth of the
anti-inﬂuenza virus antibody response is further limited
by the original antigenic sin in that every immunization
also boosts the memory response to the priming strain
[2]. Indeed, Lessler and colleagues stated that in humans,
repeated exposure to different H3N2 strains increased
antibody titers to strains encountered earlier in life [3].
Heterosubtypic antibodies—that is, antibodies recog-
nizing HAs from different subtypes—are rare [4]: In
human prevaccination sera, only 0.01% of total serum
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immunoglobulin G has been described to have heterosubtypic
binding activity, one-tenth of which is speciﬁc for the HA stem
epitope [4–6]. To establish the prevalence and predictors for
heterosubtypic antibody responses, serum from 305 human
immunodeﬁciency virus–negative volunteers was collected
in October 2009. In these serum samples, we assessed both
binding to 5 human and 3 nonhuman inﬂuenza isolates, and
neutralizing antibody titers to 5 human and 4 nonhuman
inﬂuenza isolates. These data were put into relation with epide-
miological information acquired with a questionnaire at the
time of the blood draw.
METHODS
Procedures
Sera from 305 randomly selected healthy volunteers were prospec-
tively collected in Zurich, Switzerland, in late 2009 before the ar-
rival of the inﬂuenza A(H1N1) 2009 pandemic strain (H1pdm/
09). The study was approved by the ethics committee of the Uni-
versity Hospital Zurich and written informed consent was ob-
tained from all study participants. Self-reported demographic
data including age, sex, travel history, the total number of estimat-
ed previous inﬂuenza vaccinations, estimated times of inﬂuenza
infections (deﬁned as “ﬂu” with >3 bedridden days and high
fever), and potential contact to inﬂuenza-infected birds were col-
lected on the day of the blood draw (an English translation of the
questionnaire is given in the Supplementary Methods). As anti-
bodies binding to avian or extinct human HA subtypes are
bona ﬁde cross-reactive, we determined binding antibody titers
to recombinant trimeric HA protein from rH1pdm/09, rH2/57,
Figure 1. Vaccination-dependent differences in binding antibody titers (−log[EC50]) against recombinant human and avian inﬂuenza hemagglutinin. Serum
antibody reactivities to the indicated immobilized recombinant hemagglutinins were assessed by enzyme-linked immunosorbent assay. Two-sample t test
analyses of the data were performed and showed higher binding antibody titers to the human subtypes rH1/34 and rH3/99, to heterosubtypic rH1pdm/09
and rH2/57, and to avian heterosubtypic rH5/04 titers in the vaccinated cohort. Values are shown as logarithm of the reciprocal serum dilution giving a half-
maximal signal (−log[EC50]). Median and P values of each group are indicated by numbers. Box plots represent median and interquartile range (IQR);
whiskers depict lower or upper quartile ± 1.5 × IQR. Abbreviation: EC50, half-maximal effective concentration.
Table 1. Cohort Characteristics (N = 305)
Characteristic No. (%) or Median [IQR]
Sex, female 156 (51.15)
Age, y 36 [28–49]
No. of vaccinations 2 [0–5]
No. of episodes 2 [0–3]
Contact to FPV-infected poultry 3 (0.98)
Travel to rural region in southeastern Asia 23 (7.54)
Novartis vaccine trial 17 (excluded)
“Swine flu” (H1pdm/09) infection 0
Abbreviations: FPV, fowl plague virus; IQR, interquartile range.
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rH4/56, rH5/04, rH7/79, and rH12/76 by enzyme-linked immu-
nosorbent assay (ELISA) and put them into relation to homotypic
antibodies to rH1/34 and rH3/99. In addition, we assessed wheth-
er antibodies binding to recombinant protein can also bind im-
mobilized puriﬁed H7N7 virions (H7vir/79; Supplementary
Figure 3). The half-maximal effective dose (EC50) was then deter-
mined by nonlinear regression of optical density values and used
for statistical analyses as well as to establish correlations with the
information collected in the questionnaire.
Strains used for neutralization assays are described in the
Supplementary Data. For evaluation, the reciprocal 50% inhib-
itory dose was determined by nonlinear regression to the loga-
rithm of serum concentration (−log[IC50]), where possible. If
most samples did not reach signal saturation, and constrained
nonlinear regression would have been prone for ﬁtting artifacts,
the inhibition percentage at the second serumdilution (1:90) was
taken as a surrogate value. Statistical analyses were performed as
outlined in the Supplementary Methods. R scripts used for this
study are available at https://github.com/ozagordi/FluAbs.
RESULTS
For the analysis of the prevalence and predictors of heterosubtypic
antibodies, a random study population was compiled (n = 305;
Table 1). At a serum dilution corresponding to the detection
level of natural antibodies [7] and a relaxed threshold (3-fold
over background), between 99% and 100% of individuals, de-
pending on the antigen tested, scored positive for serum antibody
binding, including all heterosubtypic HAs. Also at more stringent
conditions of 1 in 90, 98%–100% of individuals scored positive. If
a more stringent threshold of a half-maximal signal was applied,
heterosubtypic speciﬁcity could be monitored in 32%–99% (at 1
in 30) and 0.3%–79% (at 1 in 90) of the participants. The corre-
sponding values are depicted in Supplementary Figure 1.
With the exception of rH12/76, binding titers to the avian
strains (rH4/56, rH5/04, and rH7/79) were low compared
with human HAs. Low titers were also observed against
rH1pdm/09 that had not yet arrived in Switzerland when the
blood was collected. Titers against human rH2/57 that became
Figure 2. Differences in serum half-maximal inhibitory titer −log(IC50) in vaccinated and nonvaccinated individuals against human and avian inﬂuenza
subtypes. Serum antibody neutralizations against the indicated viral subtypes were assessed in neutralization assays. Two sample t test analysis were
performed and showed higher neutralizing antibody titers to all homotypic viruses (H1/07, H1/34, H3/68, and H3/07) and to heterosubtypic avian virus H5/
04 in the vaccinated cohort. No improvement in titers for human heterosubtypic H2/57 and for avian H4/56 or H7/79 viruses was found. Values are shown as
logarithm of the reciprocal serum dilution giving a half-maximal inhibitory concentration (IC50), and as inhibition percentage against H5/57 and H7/79 at a
serum dilution of 1 in 90. Median and P values are indicated. Box plots indicate median and interquartile range (IQR); whiskers include lower or upper
quartile ± 1.5 × IQR.
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extinct in 1968 were also found to be relatively low, although
distributed over a wide range of values.
To determine the direct antiviral activity of these antibodies,
we performed in vitro neutralization assays against H1/34, H1/
07, H2/57, H3/07, H3/68, H4/56, H5/04, and H7/79 viruses.
The highest neutralizing titers were found against homologous
human strains (H1/34, H1/07, H2/57, H3/68, and H3/07; Sup-
plementary Figure 1C and Supplementary Table 1). Titers to
avian H4/56 were much lower, and the barely detectable neu-
tralizing activity to H5 and H7 even prevented computation
of the log(IC50) values. Instead, the percentage of inhibition at
the ﬁrst dilution (1 in 90) was taken as a comparative proxy
value for these viruses (Supplementary Figure 1D).
ELISA titers and neutralizing activity correlated well in that
high titers in ELISA are indicative for high neutralizing activity
(Supplementary Table 2). Vaccinated individuals clearly dis-
played higher binding and neutralizing titers against human
subtypes H1/34, while still showing increased titers against
rH2/57, rH3/99, and H3/68 (Figures 1 and 2), albeit less mark-
edly. As highlighted in the regression analysis, some of these
differences may be explained by age alone (Table 2). Vaccinated
individuals also displayed signiﬁcantly higher neutralizing titers
against H1/07 and H3/07 than nonvaccinated individuals. They
also displayed higher binding antibody titers to heterosubtypic
rH1pdm/09 and rH5/04 (Figure 1). Vaccination showed no or
weaker effect on binding titers against the remaining 3 tested
heterosubtypic rHAs.
The effect of age, inﬂuenza episodes, and sex was also ana-
lyzed (Tables 3 and 4). As an exploratory data analysis, we strat-
iﬁed the age in 3 different categories according to the different
inﬂuenza pandemics: baseline, born 1969–2009 (age 0–40); cat-
egory 1, born 1958–1968 (age 41–51); category 2, born 1919–
1957 (age 52–90). After adjusting the model for age, inﬂuenza
episodes, and sex, vaccination still remained a predictor for
higher binding and neutralizing titers to the same subtypes as
in the two-sample t test. However, the impact of vaccination
was lost for rH2/57 binding and H3/68 neutralizing titers in
the adjusted models (Tables 3 and 4).
We then performed linear regression to correlate the age of
donors and the vaccination status with binding and neutralizing
antibody titers (Supplementary Figure 2 and Table 2).
Binding titers to human strains all increased with age, while
increasing only in 2 of 5 nonhuman strains, all of these phylo-
genetically close to the human ones (H1pdm/09 and H5/04).
Neutralizing titers were also found to increase with age in 2
of 5 human strains tested (H2/57 and H3/68). In contrast, titers
to heterosubtypic strains did not display a dependence on age.
Similarly, vaccination showed a positive correlation in
binding and neutralizing titers to most human strains, with
the exception of the neutralizing titers to H3/68, which were
Table 2. Linear Regression Analyzing the Impact of Age and Vaccination on Binding and Neutralizing Antibody Titers
Subtype rHAs and Strains Intercept Age (α) Vaccination (β) Interaction (γ)
Human
Binding rH1/34 1.80 ± 0.067 0.0081 ± 0.0017 0.33 ± 0.041
rH2/57 0.029 ± 0.0007
rH3/99 3.58 ± 0.099 −0.0096 ± 0.0025 0.21 ± 0.062
Neutralization H1/34 2.92 ± 0.043 0.21 ± 0.054
H1/07 2.34 ± 0.070 0.54 ± 0.087
H2/57 1.83 ± 0.12 0.019 ± 0.0032 −0.55 ± 0.16 0.012 ± 0.0040
H3/68 1.64 ± 0.097 0.027 ± 0.0024
H3/07 2.47 ± 0.065 0.24 ± 0.082
Heterosubtypes
Binding rH1pdm/09 1.19 ± 0.065 0.0047 ± 0.0016 0.18 ± 0.041
rH4/56 1.62 (IQR = 0.68)
rH5/04 0.93 ± 0.099 0.013 ± 0.0025 0.27 ± 0.062
rH7/79 1.64 (IQR = 0.36)
rH12/76 2.22 (IQR = 0.62)
Neutralization H5/04 1.36 ± 1.05 3.62 ± 1.34
H7/79 11.5 (IQR = 17.5)
Binding titers −log(EC50) and neutralizing titers −log(IC50) were modeled as a linear function of age, vaccination, and their interaction (intercept + α ×
age + β × vaccination + γ × age × vaccination). The age is given in years and vaccination is a binary dummy variable. Starting from the complete model,
coefficients not significantly different from zero (at the 1% level) were dropped and the model estimated again. The table reports the parameter estimates for
the final model. Where no effect of age and/or vaccination was detected, median and interquartile range are reported in the intercept column.
Abbreviations: EC50, half-maximal effective concentration; IC50, half-maximal inhibitory concentration; IQR, interquartile range; rHAs, recombinant hemagglutinins.
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independent of vaccination (Figure 3 and Table 2). Titers to
H2/57 were distinct, as binding titers did not depend on vacci-
nation, and neutralizing titers showed a modest interaction be-
tween age and vaccination status. Speciﬁcally, neutralizing titers
to H2/57 increased with age for both vaccinated and nonvacci-
nated groups, but were more pronounced in the vaccinated
group. As both H2 and H5 subtypes have never been included
in the vaccines, the fact that vaccination had a positive correla-
tion with neutralizing titers to these subtypes can be explained
by their phylogenetic proximity to the H1 subtype, which is part
of the widely used split vaccine formulation.
To expose differences between age groups that would go un-
detected in linear regression, we performed Loess smoothing on
antibody titers in relation to age separately for vaccinated and
nonvaccinated donors. Neutralizing titers to recent human iso-
lates (H1/07 and H3/07) were higher in vaccinees, but overall
not inﬂuenced by age (as already suggested by linear regres-
sion). However, nonlinear regression revealed that the youngest
participating donors (approximately <30 years) clearly showed
the highest titers (Figure 3). Similar ﬁndings were made for
binding titers to recently isolated H3/99. This was in contrast
to the behavior observed against older isolates (H2/57 and
H3/68); here the best neutralizing titers were found in those do-
nors who were in their ﬁrst decade of life when the correspond-
ing isolate had been circulating (ages 50–61 and 41–50,
respectively). The same trend emerged for binding titers to
H2/57. In contrast, for an older H1 isolate (H1/34), this effect
was less pronounced for both neutralizing and binding titers.
DISCUSSION
Our study demonstrates that heterosubtypic antibodies against
inﬂuenza viruses—that is, antibodies recognizing hemaggluti-
nin from multiple subtypes—can be found in most exposed
or immunized individuals. These ﬁndings corroborate previous
ﬁndings made by biochemical analysis of a limited number of
samples [4, 8]. We have found that vaccination not only
enhanced antibody responses to subtypes that are currently
circulating, and are therefore included in the vaccine, but
also augmented binding and neutralizing antibody titers to
Table 3. Multivariable Regression Analysis of Binding Titers
With Respect to Age Group and Vaccination Status
rHA Characteristics
Regression Coefficient
(95% CI)
P
Value
rH1/34 Vaccination (≥1) 0.35 (.27–.43) <.001
Age (41–51) 0.11 (.016–.21) .023
Age (52–90) 0.23 (.13–.33) <.001
rH2/57 Vaccination (≥1) 0.12 (−.10 to .33) .267
Age (41–51) 0.53 (.28–.78) <.001
Age (52–90) 1.12 (.86–1.38) <.001
rH3/99 Vaccination (≥1) 0.19 (.070–.31) .002
Age (41–51) −0.11 (−.26 to .038) .145
Age (52–90) −0.25 (−.40 to −.095) .002
rH1pdm/
09
Vaccination (≥1) 0.20 (.11–.29) <.001
Age (41–51) 0.15 (.048–.26) .004
Age (52–90) 0.14 (.033–.25) .011
rH4/56 Vaccination (≥1) 0.062 (−.14 to .26) .543
Age (41–51) 0.34 (.096–.58) .006
Age (52–90) 0.20 (−.055 to .45) .125
rH5/04 Vaccination (≥1) 0.28 (.16–.40) <.001
Age (41–51) 0.35 (.21–.49) <.001
Age (52–90) 0.33 (.18–.48) <.001
rH7/79 Vaccination (≥1) −0.015 (−.086 to .055) .667
Age (41–51) −0.041 (−.13 to .044) .347
Age (52–90) −0.065 (−.15 to .020) .148
rH12/76 Vaccination (≥1) 0.11 (−.0037 to .23) .058
Age (41–51) −0.027 (−.16 to .11) .704
Age (52–90) −0.11 (−.25 to .034) .052
Reference age: 0–40 years.
Abbreviations: CI, confidence interval; rHA, recombinant hemagglutinin.
Table 4. Multivariable Regression Analysis of Neutralizing Titers
With Respect to Age Group and Vaccination Status
Virus Characteristics
Regression Coefficient
(95% CI)
P
Value
H1/34 Vaccination (≥1) 0.27 (.15–.39) <.001
Age (41–51) 0.017 (−.12 to .16) .809
Age (52–90) 0.099 (−.048 to .25) .185
H1/07 Vaccination (≥1) 0.66 (.47–.85) <.001
Age (41–51) −0.073 (−.30 to .15) .524
Age (52–90) −0.074 (−.31 to .16) .536
H2/57 Vaccination (≥1) −0.085 (−.18 to .013) .089
Age (41–51) 0.46 (.34–.57) <.001
Age (52–90) 0.96 (.83–1.082) <.001
H3/68 Vaccination (≥1) 0.022 (−.094 to .14) .708
Age (41–51) 0.85 (.71–.99) <.001
Age (52–90) 0.73 (.59–.88) <.001
H3/07 Vaccination (≥1) 0.40 (.106–.69) .008
Age (41–51) 0.094 (−.26 to .45) .597
Age (52–90) −0.096 (−.46 to .27) .604
H4/56 Vaccination (≥1) 0.034 (−.058 to .13) .464
Age (41–51) 0.085 (−.026 to .20) .133
Age (52–90) 0.14 (.021–.25) .021
H5/04 Vaccination (≥1) 3.43 (.76–6.10) .012
Age (41–51) 0.71 (−2.50 to 3.92) .664
Age (52–90) 0.39 (−2.94 to 3.72) .818
H7/79 Vaccination (≥1) −1.059 (−4.091 to 1.97) .492
Age (41–51) 0.71 (−2.95 to 4.34) .708
Age (52–90) 3.32 (−.64 to 7.11) .085
Reference age: 0–40 years.
Abbreviation: CI, confidence interval.
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heterosubtypic subtypes. Senior people had higher antibody
titers to old homosubtypic inﬂuenza isolates than their younger
counterparts, whose antibody response appeared to favor more
recent isolates. Age was also found to be a predictor with a
positive coefﬁcient for higher antibody titers to heterosubtypic
isolates. In contrast, the number of self-reported inﬂuenza
Figure 3. Loess smoothing of antibody titers. A, The binding antibody titers for rH3/99, but not for rH1/34 or rH2/57, were lower in more seasoned
individuals. Smoothing discovers steep increase of −log(EC50) around age 40 for rH2/57. For rH1/34, smoothing displayed results similar to linear regres-
sion. Highest −log(EC50) titers to rH3/99 are depicted in individuals aged 21–27 years. Values are shown as logarithm of the reciprocal serum dilution in
correlation with age. B, Neutralizing titers to H1/34 (vaccinated), H2/57 (vaccinated and nonvaccinated), and H3/68 (vaccinated and nonvaccinated) in-
creased with increasing age. The −log(IC50) to H1/07 (vaccinated) decreased with increasing age (compare with Supplementary Figure 2). Remaining sub-
types do not show slopes different from zero. Smoothing of −log(IC50) for H2/57 discovered a peak at age 50. Values are shown as logarithm of the
reciprocal serum dilution giving a half-maximal inhibitory concentration in correlation with age, and, separated by bold frame lines, as inhibition percentage
against H5/57 and H7/79 at a serum dilution of 1 in 90. Blue triangles and lines represent the vaccinated cohort; black squares and lines represent the
nonvaccinated cohort. Gray shaded areas indicate the conﬁdence band. Signiﬁcance codes (testing the slope being different from zero): ***P < .001,
**P < .01, * P < .05. Abbreviations: EC50, half-maximal effective concentration; IC50, half-maximal inhibitory concentration.
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episodes did not correlate with higher antibody titers, which,
given the unreliability of the parameter, is not surprising. More-
over, because vaccinations, like inﬂuenza episodes, also accumu-
late with age and may not always be reported accurately, it is hard
to disentangle their effect on the antibody titers. For this reason,
vaccination status was reported as binary (vaccinated/nonvacci-
nated), discarding differences in the number of vaccinations.
As the participants of our study have not recently been vac-
cinated, their antibody repertoire is not skewed toward a recent-
ly inoculated vaccine strain. Attention is therefore focused on
the serum antibody composition present when infection is
most likely to occur. The use of viable viruses for neutralization
assays rather than highly neutralization-sensitive pseudotyped
virions further assured that the neutralizing activity detected
is biologically relevant [9].
At the time of serum sampling, H1pdm/09 had not yet reached
Switzerland. Potential H1pdm/09-related induction of broadly
cross-reactive antibodies [10] is therefore unlikely to have skewed
our results. Yet, our data are consistent with ﬁndings that H1pdm/
09 possesses an epitope that is shared with the H1N1 virus strains
circulating before 1957; individuals born before 1957 had higher
titers to H1pdm/09 than younger participants [11, 12]. Although
the binding titers were expected to increase with age in the non-
vaccinated cohort, no peak in elderly persons appeared in non-
parametric smoothing. Both observations, however, could be
explained by the low sample size in this age group (Figure 3).
Because we used a novel neutralization assay, we cannot give
predictions for protection. In the hemagglutinin inhibition assays
(HIAs), a serum dilution of 1:40 is considered protective whereas
comparable values were found for an ELISA-based and a color-
imetric microneutralization assay; however, these values are not
applicable to our assay [13], in particular as it was also shown that
ELISA values and HIA values do not correlate, not even within
the same subtypes [14].Moreover, because the majority of heter-
osubtypic antibodies was found to bind a conserved epitope in
the stem of the HA protein and did not interfere with hemagglu-
tination [15, 16], they would not be detected by HIAs. Conse-
quently, no direct predictions for heterosubtypic protection can
be drawn from our dataset at this point. Further research will be
required to deﬁne this relationship.
In contrast, the large number of serum samples tested for
both binding and neutralization allowed us the establishment
of a linear relationship: Increasing titers of binding antibodies
correlate statistically signiﬁcant with increasing neutralizing ti-
ters (Supplementary Table 2). The correlation coefﬁcient for ex-
tinct human strains was reasonably high, especially in rH2/57 vs
H2/57 (R = 0.43), whereas isolates with very distant isolation
years (H3/68 vs rH3/99) did not correlate at all, despite
belonging to the same subtype.
Lessler and colleagues found that repeated exposure to dif-
ferent H3N2 strains increased antibody titers to those strains
encountered earlier in life, whereas progressively fewer speciﬁc
antibodies to subsequent infection are made with age [3]. We
could conﬁrm this ﬁnding in that the neutralizing and binding
titers were the highest in those individuals who were in their
ﬁrst decade of life during the period of time when the corre-
sponding subtype was circulating. Older individuals also had
signiﬁcantly more binding and neutralizing antibodies against
old than against more recent isolates (eg, H3/99; Supplementary
Figure 2), which may reﬂect original antigenic sin [17]. In con-
trast, in line with other studies [18], we found antibody titers to
the last prestudy isolates (2007) to be the same in all age groups.
In elderly individuals, vaccination increased the probability of
having heterosubtypic antibodies. Thus, whereas senescence of
the immune system presumably contributed to a poorer response
to recent isolates, age was advantageous for the development of
heterosubtypic antibodies (to both human and nonhuman iso-
lates). Vaccination always improved titers in the oldest or middle
age group compared with young individuals. Although the age at
which the vaccinations were received was not assessed, most indi-
viduals received them in the previous 5–10 years. In fact, inﬂuenza
vaccination was very uncommon in Switzerland prior to the late
1990s [19]. Our ﬁndings show that vaccination is of value also in
more seasoned individuals, and that its beneﬁt is not just the result
of vaccinations at younger age. This provides additional, albeit
indirect, support for annual vaccinations in elderly individuals.
Although most humans have low levels of heterosubtypic an-
tibodies, they are still susceptible to infection with antigenically
drifted or shifted inﬂuenza A strains, indicating that these anti-
bodies probably are not protective. However, such antibodies
are likely to attenuate disease, but to prove this hypothesis,
large clinical trials would need to be conducted. The ﬁndings
of our study nonetheless clearly indicate that novel vaccination
strategies targeting the conserved epitopes of inﬂuenza hemag-
glutinin could proﬁt from preexisting antigen-experienced het-
erosubtypic B cells. Our data also unambiguously support
yearly vaccination as neutralizing antibody titers increase over
time in elderly and younger people and, furthermore, as more
heterosubtypic antibodies are induced.
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